Based on this YouTube video's total view count of 1.35M views and industry-standard rates, the estimated total earning is $949 - $2.71K through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore International data agrees with 1,356,236 views, 39,561 likes, and 6,289 comments. Experience the impact of this video content that has captured audience attention.

Omicron is less severe and natural immunity works Link to free download of my 2 textbooks http://159.69.48.3/ Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California https://www.medrxiv.org/content/10.1101/2022.01.11.22269045v1 https://www.medrxiv.org/content/10.1101/2022.01.11.22269045v1.full.pdf Background The Omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly achieved global dissemination, accounting for most infections in the United States by December 2021. November 30, 2021 to January 1, 2022, Delta v Omicron Using S gene target failure (SGTF) (99.7%) Hospital admission Lengths of hospital stay Hospital admissions associated with new-onset respiratory symptoms Intensive care unit (ICU) admission Mechanical ventilation Mortality Group 1, omicron N = 52,297, cases with Omicron variant infections Hospital admissions, 235 (0.5%) Mean follow-up, 5.5 days 88 admitted ITU, 7 Ventilated, 0 Deaths, 1 Length of hospital stay, 3.4 days (70%) less than delta Group 2, non – omicron (delta) N = 16,982, cases with Delta variant infections Hospital admissions, 222 (1.3%) Mean follow-up, 15.8 days 189 admitted ITU, 23 Ventilated, 11 Deaths, 14 Also Omicron variant infection, reduced risk of hospitalization across age and comorbidity categories Risk of symptomatic hospitalization was markedly reduced among cases who had tested positive for SARS-CoV-2 infection ≥90 days prior Intrinsically less severe infection Less severe in vaccinated and unvaccinated Evidence for a reduction in severe outcomes among vaccinated cases with both Delta and Omicron variant infections in our study suggests substantial public health benefits from continued COVID-19 vaccination. Dutch data https://twitter.com/marionkoopmans/status/1472470129350955012 https://t.co/TJ6peBST2I Common cold protection https://www.imperial.ac.uk/news/233018/cells-from-common-colds-cross-protect-against/ Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts https://www.nature.com/articles/s41467-021-27674-x.pdf https://www.nature.com/articles/s41467-021-27674-x Cross-reactive immune responses to SARS-CoV-2 52 COVID-19 household contacts We enumerate the frequency of specific T cells Spike, nucleocapsid, membrane, envelope and ORF1, that cross-react with human endemic coronaviruses Nucleocapsid-specific T cells Limited protective function of spike-cross-reactive T cells Our results are thus consistent with, pre-existing non-spike cross-reactive memory T cells, protecting SARS-CoV-2-naïve contacts from infection, thereby supporting the inclusion of non-spike antigens in second-generation vaccines.

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.